Free Newsletter
FDA reform doesn't top Obama's list
After years of food poisoning episodes, tainted imports and unrealized promises of reform, the incoming Obama administration has been saying the embattled FDA would finally get what it needed. But now, some of the leading champions of rebuilding the agency and the food safety system acknowledge that big reforms are likely still years away. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: